Navigation Links
Shire plc: Excellent Performance Across All Areas of the Business and Accelerating New Product Sales Drive Revenue Growth of 36%
Date:2/21/2008

rtainties and are subject to change at any time. In the event such risks or uncertainties materialize, Shire's results could be materially affected. The risks and uncertainties include, but are not limited to, risks associated with: the inherent uncertainty of pharmaceutical research; product development including, but not limited to, the successful development of JUVISTA(R) (Human TGF beta 3) and velaglucerase alfa (GA-GCB); manufacturing and commercialization including, but not limited to, the establishment in the market of VYVANSE(TM)(lisdexamfetamine dimesylate) (Attention Deficit and Hyperactivity Disorder ("ADHD")); the impact of competitive products including, but not limited to, the impact of those on Shire's ADHD franchise; patents including, but not limited to, legal challenges relating to Shire's ADHD franchise; government regulation and approval including, but not limited to, the expected product approval date of INTUNIV(TM) (guanfacine extended release) (ADHD); Shire's ability to secure new products for commercialization and/or development; and other risks and uncertainties detailed from time to time in Shire plc's filings with the Securities and Exchange Commission, particularly Shire plc's Annual Report on Form 10-K for the year ended December 31, 2006.

Non GAAP Measures

This press release contains financial measures not prepared in accordance with US GAAP. These measures are referred to as "non GAAP" measures and include Non GAAP operating income, Non GAAP net income, Non GAAP diluted earnings per ordinary share, Non GAAP diluted earnings per ADS, Non GAAP R&D, Non GAAP SG&A and effective tax rate on Non GAAP income. These non GAAP measures exclude the effect of certain cash and non-cash items, both recurring and non-recurring, that Shire's management believes are not related to the core performance of Shire's business.

These non GAAP financial measures are used by Shire's management to make operating decisions because they facil
'/>"/>

SOURCE Shire plc
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33

Related biology technology :

1. Shire plc: Correction Re Website
2. Shires ELAPRASE(R) (idursulfase) Approved in Mexico for Treatment of Hunter Syndrome
3. Shire Engages Palio
4. Texas Boy Receives Wheelchair From New Hampshire Couples Recently Deceased Granddaughter
5. FDA Approves Additional Dosage Strengths of Shires ADHD Treatment VYVANSE(TM) (lisdexamfetamine dimesylate) Which May Help Physicians Tailor Treatment for Individual Patients
6. Shire Expands its Gastrointestinal Portfolio Through In-Licensing Celiac Disease Phase 2 Product From Alba Therapeutics Corporation
7. Alba Therapeutics Corporation and Shire plc Enter Into $325 Million ex-US, ex-Japan Licensing Agreement to Develop and Commercialize AT-1001
8. Shire plc: Board Changes
9. David Mott Appointed Non Executive Director at Shire
10. Correction: Shire plc: Third Quarter 2007 results date notification November 1, 2007
11. Shire Divests Non-Core Product Portfolio to Almirall
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/6/2015)... Whitefox ( http://www.whitefox.com ... has signed an agreement with  California ... the delivery of an industrial scale membrane system. The ... water, energy and emissions in the production ... project is fully aligned with ...
(Date:5/6/2015)... OR (PRWEB) May 06, 2015 ... search and growth strategy for the specialty pharmacy industry, ... of the 2015 Armada Specialty Pharmacy Summit. The Summit ... Hotel in Las Vegas and is the largest annual ... will be in attendance, from pharmacy providers, pharma/biotech manufacturers, ...
(Date:5/5/2015)... SAN DIEGO AND TORONTO, May 5, 2015 /PRNewswire/ - Aptose ... "Company") today reported financial results for the three months ... Unless specified otherwise, all amounts are in Canadian dollars. ... changed its fiscal year end from May 31 to ... current interim period being reported is for the three ...
(Date:5/5/2015)... CA (PRWEB) May 05, 2015 ... Life Science Animal Health, Jeffrey Schaffer, DVM, as ... “With over 15 years of experience in the ... a great addition to our veterinarian lead organization”. ... Officer, explains. “Dr. Schaffer will be responsible for ...
Breaking Biology Technology:Whitefox Signs Agreement With Pacific Ethanol Inc. 2The Remedy Group presenting at the 2015 Armada Specialty Pharmacy Summit: The Pitfalls to Growth and Maintaining the Patient Experience 2Aptose Biosciences Reports Results for the First Quarter Ended March 31, 2015 2Aptose Biosciences Reports Results for the First Quarter Ended March 31, 2015 3Aptose Biosciences Reports Results for the First Quarter Ended March 31, 2015 4Aptose Biosciences Reports Results for the First Quarter Ended March 31, 2015 5Aptose Biosciences Reports Results for the First Quarter Ended March 31, 2015 6Aptose Biosciences Reports Results for the First Quarter Ended March 31, 2015 7Aptose Biosciences Reports Results for the First Quarter Ended March 31, 2015 8Leading Regenerative Veterinary Medicine Company, VetStem Biopharma announces the addition of Dr Jeffrey Schaffer as the Director of Veterinary Professional Services. 2
... CITY, Feb. 12 /PRNewswire-FirstCall/ - AEterna Zentaris Inc.,(NASDAQ: ... company focused on,endocrine therapy and oncology, today reported ... agonist linked to doxorubicin,has commenced in its Phase ... had begun in December 2007. This open-label,non-comparative multi-center ...
... Candidates Featured -, SOUTH SAN FRANCISCO, Calif., ... company focused on the discovery,and development of monoclonal ... been selected for presentation at the meeting,of American ... Diego on,April 12-16, 2008., "We are pleased ...
... 12 Nektar,Therapeutics (Nasdaq: NKTR ) announced ... a drug delivery service provider to a,therapeutics drug ... corporate functions, and strengthen,decision-making and execution within the ... a world-class drug development company,and these changes are ...
Cached Biology Technology:AEterna Zentaris Reports First Patients Treated with Anti-Cancer Compound AEZS-108 in Phase 2 Trial in Ovarian and Endometrial Cancers 2AEterna Zentaris Reports First Patients Treated with Anti-Cancer Compound AEZS-108 in Phase 2 Trial in Ovarian and Endometrial Cancers 3AEterna Zentaris Reports First Patients Treated with Anti-Cancer Compound AEZS-108 in Phase 2 Trial in Ovarian and Endometrial Cancers 4Raven biotechnologies to Provide Updates on Oncology Pipeline With Four AACR Presentations 2Raven biotechnologies to Provide Updates on Oncology Pipeline With Four AACR Presentations 3Nektar Announces Restructuring to Complete Its Transition to a Therapeutics Drug Development Organization 2Nektar Announces Restructuring to Complete Its Transition to a Therapeutics Drug Development Organization 3
(Date:4/14/2015)... April 14, 2015  HYPR Corp. today announced ... ® ) Alliance tm , an industry consortium ... commit to share technology and collaborate to deliver ... interoperable, more secure and private, and easier to ... verification that protects sensitive user information and eliminates ...
(Date:4/10/2015)... Research and Markets ( http://www.researchandmarkets.com/research/cjk4gb/security ... Competitive Profiles - NEC" report to their offering. ... will continue to supply a range of IT security ... company focus on the development of a Big Data ... in the Asia-Pacific region is ...
(Date:4/2/2015)... In the current eight ... the strongest competitors, showing outstanding performance in recognition ... is capable of a throughput of 5.000.000 fingerprints ... be ten times faster than most competitors and ...      (Photo: http://photos.prnewswire.com/prnh/20150402/738673-a ) , ...
Breaking Biology News(10 mins):HYPR Corp. Joins the FIDO Alliance 2HYPR Corp. Joins the FIDO Alliance 3NEC Security Competitive Profile 2015 2DERMALOG AFIS Emerges as Performance Winner in NIST Benchmark Test 2DERMALOG AFIS Emerges as Performance Winner in NIST Benchmark Test 3
... A world-class St. Augustine spa called “perfect” by past ... a “perfect 10” business opportunity for entrepreneurs with an eye for beauty and ... Designed by renowned ... is part of the highly-rated Laterra Resort, located in the World Golf Village ...
... April 27 /PRNewswire-FirstCall/ - Aeterna Zentaris Inc. (NASDAQ: ... development company specialized in oncology and endocrinology, announced today that ... notifying it that the closing price per share of the ... bid price for 10 consecutive trading days and that, as ...
... be able to survive the harsh environs of Mars ... according to research published in the April 2010 issue ... The search for life on Mars remains a ... Institutes. To preserve the pristine environments, the bioloads on ...
Cached Biology News:Plastic Surgeons Rate Auction of World-Class Florida Laterra Spa May 21 a 'Perfect 10,' Great Business Opp for Celebrity Retreat 2Plastic Surgeons Rate Auction of World-Class Florida Laterra Spa May 21 a 'Perfect 10,' Great Business Opp for Celebrity Retreat 3Plastic Surgeons Rate Auction of World-Class Florida Laterra Spa May 21 a 'Perfect 10,' Great Business Opp for Celebrity Retreat 4
... Tecans state-of-the-art software for all your biopharmaceutical ... in a single, scalable software package. The ... simplifying the control of all Freedom instruments ... EVO 100 with one liquid handling arm ...
... Kit is an advanced system for isolating DNA from ... be used directly for any downstream application. ... to use in 56 minutes Low melting point ... and TBE gels No specialised equipment required ...
... in hybridization incubators with rotators. Graduated, ... size PP plug-seal screw-cap with O-ring ... three lengths to accept different size ... O-rings available separately. • Comp Dim: ...
... efficient extraction of DNA fragments from 150 bp to ... procedure uses GelMelt solution to dissolve the gel slice, ... membrane in a spin column format. After a wash ... Each spin column can bind up to 20 g ...
Biology Products: